REG - Indivior PLC - Appointment of Independent Non-Executive Director

IndiviorAnnouncement

27/04/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220427:nRSa4482Ja&default-theme=true

RNS Number : 4482J  Indivior PLC  27 April 2022

Indivior PLC

Appointment of Independent Non-Executive Director

 

Slough, UK, and Richmond, VA, April 27, 2022 - The Board of Indivior PLC today
announces the appointment of Barbara Ryan as an Independent Non-Executive
Director of the Company with effect from June 1, 2022.

 

Graham Hetherington, Chair, commented:

'We are pleased to have Barbara join Indivior's Board as an Independent
Non-Executive Director. With over 40 years of experience in US healthcare
capital markets, she will be a tremendous asset as we look to broaden
Indivior's awareness in the US.  She will also bring important perspectives
as we seek to grow Indivior through potential business development
opportunities.'

 

Barbara was a Wall Street sell-side research analyst covering the US Large Cap
Pharmaceutical Industry for more than 30 years before founding Barbara Ryan
Advisors, a capital markets and communications firm, in 2012. Barbara has deep
experience in equity and debt financings, M&A, valuation, SEC reporting,
financial analysis and corporate strategy across a broad range of life
sciences companies. Barbara is also the Founder of Fabulous Pharma Females, a
non-profit organization whose mission is to advance women in the biopharma
industry.  Barbara is a Senior Advisor at EY and is currently a Non-Executive
Director of INVO Bioscience (Nasdaq: INVO) and MINK Therapeutics (Nasdaq:
INKT).

 

There is no further information to disclose in relation to Barbara Ryan's
appointment in accordance with LR 9.6.13.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 900
individuals globally and its portfolio of products is available in over 40
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=04%7C01%7Cjason.thompson%40Indivior.com%7Ce5a2346f599647fe3cb508da1313b444%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843272586689780%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=NeCTaN7pU6ff80%2FsJk2McsieAZpjnyWU87dggeEV8kA%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=04%7C01%7Cjason.thompson%40Indivior.com%7Ce5a2346f599647fe3cb508da1313b444%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843272586689780%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=PI4QgbGT1LYYngXcQY1Bzz58oywHbuEMAVsABbLcn0E%3D&reserved=0)
.

 

Contact:

Jason Thompson

Vice President, Investor Relations

jason.thompson@indivior.com (mailto:jason.thompson@indivior.com)

+1 804 402 7123

###

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUNRRRUBUSUUR